Mixed Early Phase III Results With Aldeyra’s First-In-Class Dry Eye Candidate

Aldeyra To Initiate Part 2 Of The Adaptive Phase III Study In 2020

The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.

Red_Eye
• Source: Shutterstock

Aldeyra Therapeutics Inc. has presented mixed top-line results from part 1 of its adaptive Phase III RENEW study of the potential first-in-class dry eye disease therapy, reproxalap, and investors have reacted cautiously to the data.

The Lexington, MA-based biotech’s share price on NASDAQ declined by 32% on 3 December to $5.06, the day the data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Sensory

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?